The clinician
prescribed erlotinib, an EGFR inhibitor, but unfortunately the patient did not respond.
Not exact matches
The drug
erlotinib is
prescribed to between 10 — 30 per cent of patients with non-small cell lung cancer, which accounts for 85 per cent of all lung cancer cases.
The drug
erlotinib is
prescribed to between 10 - 30 per cent of patients with non-small cell lung cancer, which accounts for 85 per cent of all lung cancer cases.